C1 esterase inhibitor (human) is under clinical development by Octapharma and currently in Phase II for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to GlobalData, Phase II drugs for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how C1 esterase inhibitor (human)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
C1 esterase inhibitor (human) overview
Human C1 esterase inhibitor (OCTA-C1-INH) is under development for the treatment of congenital C1-INH deficiency and hereditary angioedema. It is administered by intravenous route. It acts by targeting C1 Esterase.
Octapharma overview
Octapharma (Octapharma) is a human protein product manufacturer that focuses on developing and producing medicines through human proteins from human plasma and cell lines. The company treats patients worldwide with products across immunotherapy, hematology, and critical care therapeutic areas. It sources plasma from company-owned plasma donation centers and other external sources. Octapharma owns plasma donation centers in the US and Germany and owns production facilities in Austria, Germany, France, Mexico, and Sweden. It’s production plants carry out plasma fractionation and purification, pharmaceutical production, research and development, product labeling, packaging, storage, and distribution. Octapharma is headquartered in Lachen, Switzerland.
For a complete picture of C1 esterase inhibitor (human)’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
